Bosentan increases warfarin dosing requirements in pulmonary hypertension
نویسندگان
چکیده
منابع مشابه
Bosentan therapy for pulmonary arterial hypertension.
BACKGROUND Endothelin-1 is a potent vasoconstrictor and smooth-muscle mitogen. In a preliminary study, the orally administered dual endothelin-receptor antagonist bosentan improved exercise capacity and cardiopulmonary hemodynamics in patients with pulmonary arterial hypertension. The present trial investigated the effect of bosentan on exercise capacity in a larger number of patients and compa...
متن کاملBosentan and improved pulmonary endothelial function in pulmonary arterial hypertension.
Development (CNPq; Brasilia, Brazil; #474621/2004-9), Rio de Janeiro Research Foundation (FAPERJ; Rio de Janeiro, Brazil; #E-26/100.461/2007), and, in part, by the Zerbini Foundation (São Paulo, Brazil). L.M. Ueno was supported by FAPESP as a post-doctoral fellow (#03/10881-2); and C.E. Negrao, M.U.P.B. Rondon and A.C.L. Nobrega were supported by CNPq (#302146/2007-5, #303518/2008-1 and #301168...
متن کاملBosentan for pulmonary hypertension secondary to idiopathic pulmonary fibrosis
Pulmonary hypertension is a poor prognostic factor in patients with interstitial lung disease. No established treatment exists for pulmonary hypertension secondary to interstitial pneumonia. We describe the case of an 81-year-old woman with idiopathic pulmonary fibrosis (IPF), who was admitted to our hospital due to aggravation of dyspnea and decreased oxygen saturation, as well as onset of ort...
متن کاملBosentan in pulmonary arterial hypertension secondary to scleroderma.
OBJECTIVE . To assess the efficacy and tolerability of bosentan in pulmonary arterial hypertension secondary to systemic sclerosis (SSc-PAH) including patients with restrictive lung disease. METHODS We retrospectively reviewed 23 SSc-PAH patients with PAH at baseline [PA systolic pressure (PASP) >or= 45 mm Hg by echocardiogram or mean PA pressure > 25 mm Hg at rest by cardiac catheterization]...
متن کاملBosentan in Pediatric Patients with Pulmonary Arterial Hypertension
OBJECTIVE: In order to provide an overview of current knowledge, the literature was systematically examined for clinical studies, which evaluate the safety and effectiveness of bosentan in pediatric pulmonary arterial hypertension (PAH). SOURCES: 3 databases (MEDLINE, EMBASE and BIOSIS) were searched for the period January 2000 October 2007 using the key words 'pulmonary arterial hypertension',...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the American College of Cardiology
سال: 2003
ISSN: 0735-1097
DOI: 10.1016/s0735-1097(03)81629-7